Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R C, Goetz C G, Golbe L I, Grafman J, Growdon J H, Hallett M, Jankovic J, Quinn N P, Tolosa E, Zee D S
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-9130, USA.
Neurology. 1996 Jul;47(1):1-9. doi: 10.1212/wnl.47.1.1.
To improve the specificity and sensitivity of the clinical diagnosis of progressive supranuclear palsy (PSP, Steele-Richardson-Olszewski syndrome), the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP, Inc. (SPSP) sponsored an international workshop to develop an accurate and universally accepted set of criteria for this disorder. The NINDS-SPSP criteria, which were formulated from an extensive review of the literature, comparison with other previously published sets of criteria, and the consensus of experts, were validated on a clinical data set from autopsy-confirmed cases of PSP. The criteria specify three degrees of diagnostic certainty: possible PSP, probable PSP, and definite PSP. Possible PSP requires the presence of a gradually progressive disorder with onset at age 40 or later, either vertical supranuclear gaze palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of onset, as well as no evidence of other diseases that could explain these features. Probable PSP requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as the other features of possible PSP. Definite PSP requires a history of probable or possible PSP and histopathologic evidence of typical PSP. Criteria that support the diagnosis of PSP, and that exclude diseases often confused with PSP, are presented. The criteria for probable PSP are highly specific, making them suitable for therapeutic, analytic epidemiologic, and biologic studies, but not very sensitive. The criteria for possible PSP are substantially sensitive, making them suitable for descriptive epidemiologic studies, but less specific. An appendix provides guidelines for diagnosing and monitoring clinical disability in PSP.
为提高进行性核上性麻痹(PSP,即Steele-Richardson-Olszewski综合征)临床诊断的特异性和敏感性,美国国立神经疾病与中风研究所(NINDS)和进行性核上性麻痹协会(SPSP)主办了一次国际研讨会,以制定一套针对该疾病准确且被普遍接受的标准。NINDS-SPSP标准是在广泛查阅文献、与其他先前发表的标准进行比较以及专家共识的基础上制定的,并在一组经尸检确诊的PSP临床数据集上进行了验证。该标准明确了三个诊断确定性程度:可能的PSP、很可能的PSP和确诊的PSP。可能的PSP要求存在一种40岁及以后起病的逐渐进展性疾病,要么是垂直性核上性凝视麻痹,要么是垂直扫视减慢以及起病第一年出现明显的姿势不稳伴跌倒,且无其他可解释这些特征的疾病证据。很可能的PSP要求有垂直性核上性凝视麻痹、明显的姿势不稳和起病第一年跌倒,以及可能的PSP的其他特征。确诊的PSP要求有很可能或可能的PSP病史以及典型PSP的组织病理学证据。文中列出了支持PSP诊断且排除常与PSP混淆疾病的标准。很可能的PSP标准具有高度特异性,适用于治疗、分析性流行病学和生物学研究,但敏感性不高。可能的PSP标准敏感性较高,适用于描述性流行病学研究,但特异性较低。附录提供了PSP临床残疾诊断和监测的指南。